Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTTR1147A in Neuropathic Diabetic Foot Ulcers
NCT02833389Phase 1Completed
- Sponsor
- Genentech
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of efmarodocokin alfa in diabetic foot ulcer (DFU) (6 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants with Adverse Events. Started Nov 2016; status: completed.
02
Drugs
efmarodocokin alfa
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02833389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833389.